ValuEngine upgraded shares of Stryker (NYSE:SYK) from a hold rating to a buy rating in a research report sent to investors on Tuesday morning.
SYK has been the topic of a number of other reports. Zacks Investment Research raised shares of Stryker from a hold rating to a buy rating and set a $196.00 price objective on the stock in a research note on Friday, June 1st. Canaccord Genuity lifted their price objective on shares of Stryker from $176.00 to $185.00 and gave the company a buy rating in a research note on Friday, April 27th. Citigroup lifted their price objective on shares of Stryker from $166.00 to $171.00 and gave the company a neutral rating in a research note on Tuesday, May 1st. Morgan Stanley lifted their price objective on shares of Stryker from $179.00 to $186.00 and gave the company an overweight rating in a research note on Monday, February 26th. Finally, Evercore ISI assumed coverage on shares of Stryker in a research note on Monday, April 2nd. They issued an in-line rating and a $165.00 price objective on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating and sixteen have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $171.95.
Shares of Stryker opened at $168.97 on Tuesday, according to Marketbeat. Stryker has a 12 month low of $137.70 and a 12 month high of $179.84. The company has a market cap of $64.37 billion, a PE ratio of 26.04, a price-to-earnings-growth ratio of 2.45 and a beta of 0.71. The company has a current ratio of 1.64, a quick ratio of 1.08 and a debt-to-equity ratio of 0.64.
Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 26th. The medical technology company reported $1.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.60 by $0.08. The business had revenue of $3.24 billion for the quarter, compared to analysts’ expectations of $3.20 billion. Stryker had a net margin of 8.00% and a return on equity of 25.65%. The firm’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period last year, the firm posted $1.48 earnings per share. equities analysts predict that Stryker will post 7.23 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, July 31st. Shareholders of record on Friday, June 29th will be paid a dividend of $0.47 per share. The ex-dividend date is Thursday, June 28th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 1.11%. Stryker’s payout ratio is presently 28.97%.
In other Stryker news, insider Lonny J. Carpenter sold 5,000 shares of the business’s stock in a transaction on Friday, May 4th. The shares were sold at an average price of $166.42, for a total transaction of $832,100.00. Following the sale, the insider now owns 101,675 shares of the company’s stock, valued at $16,920,753.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Katherine Ann Owen sold 2,651 shares of the business’s stock in a transaction on Wednesday, April 18th. The stock was sold at an average price of $165.00, for a total transaction of $437,415.00. Following the sale, the vice president now directly owns 7,729 shares in the company, valued at approximately $1,275,285. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,401 shares of company stock worth $1,389,515. Insiders own 7.40% of the company’s stock.
Several large investors have recently modified their holdings of the company. River Wealth Advisors LLC lifted its holdings in shares of Stryker by 1.1% during the first quarter. River Wealth Advisors LLC now owns 29,300 shares of the medical technology company’s stock worth $4,715,000 after purchasing an additional 309 shares during the period. Mogy Joel R Investment Counsel Inc. lifted its holdings in Stryker by 0.4% in the first quarter. Mogy Joel R Investment Counsel Inc. now owns 86,568 shares of the medical technology company’s stock valued at $13,931,000 after buying an additional 325 shares during the period. Altavista Wealth Management Inc. lifted its holdings in Stryker by 1.0% in the first quarter. Altavista Wealth Management Inc. now owns 35,165 shares of the medical technology company’s stock valued at $5,659,000 after buying an additional 361 shares during the period. Rehmann Capital Advisory Group lifted its holdings in Stryker by 7.8% in the fourth quarter. Rehmann Capital Advisory Group now owns 5,306 shares of the medical technology company’s stock valued at $822,000 after buying an additional 385 shares during the period. Finally, Thrivent Financial For Lutherans lifted its holdings in Stryker by 2.4% in the fourth quarter. Thrivent Financial For Lutherans now owns 17,092 shares of the medical technology company’s stock valued at $2,646,000 after buying an additional 398 shares during the period. Institutional investors own 74.92% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.